Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer.

abstract：:As the number of women surviving breast cancer increases, with implications for the health system, research into the physical and psychosocial sequelae of the cancer and its treatment is a priority. This research estimated self-reported health-related quality of life (HRQoL) associated with two rehabilitation interven...

journal_title：Breast cancer research and treatment

authors： Gordon LG,Battistutta D,Scuffham P,Tweeddale M,Newman B

更新日期：2005-10-01 00:00:00

abstract：PURPOSE:Patients with spontaneous nipple discharge (SND) who have neither clinically palpable masses nor evidence of disease on imaging with mammogram and/or ultrasound are traditionally investigated with galactogram and duct excision. As breast imaging improves, it has raised the question whether galactography and mic...

journal_title：Breast cancer research and treatment

authors： Lustig DB,Warburton R,Dingee CK,Kuusk U,Pao JS,McKevitt EC

更新日期：2019-04-01 00:00:00

abstract：:The incidence rate of breast cancer in Japan rose more than two-fold from 1959-60 to 1983-87. To assess to what extent this increase can be explained by changes in the prevalence of four major risk factors of breast cancer (i.e. age at menarche, age at first birth, age at menopause, and parity), we estimated the proba...

journal_title：Breast cancer research and treatment

authors： Nagata C,Kawakami N,Shimizu H

更新日期：1997-05-01 00:00:00

abstract：:A major goal of cancer chemotherapy is the identification of cytotoxic compounds that are highly selective for cancer cells. We describe here one such compound - a novel iron chelator, desferri-exochelin 772SM. This desferri-exochelin has unique chemical and pharmacological properties, including extremely high iron bi...

journal_title：Breast cancer research and treatment

authors： Pahl PM,Horwitz MA,Horwitz KB,Horwitz LD

更新日期：2001-09-01 00:00:00

abstract：:The role of environmental carcinogen exposure in breast cancer development has long been suspected, but no specific association has been identified so far. A few molecular epidemiology studies reported that DNA adducts detected by different methods are associated with a modest increase of breast cancer risk. We aimed ...

journal_title：Breast cancer research and treatment

authors： Saieva C,Peluso M,Masala G,Munnia A,Ceroti M,Piro S,Sera F,Bendinelli B,Pala V,Sieri S,Tumino R,Giurdanella MC,Panico S,Mattiello A,Vineis P,Polidoro S,Matullo G,Palli D

更新日期：2011-09-01 00:00:00

abstract：:ALIQUOT (Anastrozole vs. Letrozole, an Investigation of Quality Of Life and Tolerability) was a prospective, open-label, randomized pharmacodynamic study designed to assess the effects of aromatase inhibitors (AIs) on bone turnover in healthy postmenopausal women with estrogen receptor-positive breast cancer. Ninety-f...

journal_title：Breast cancer research and treatment

authors： McCaig FM,Renshaw L,Williams L,Young O,Murray J,Macaskill EJ,McHugh M,Hannon R,Dixon JM

更新日期：2010-02-01 00:00:00

abstract：:miRNAs regulate the expression of genes in both normal physiology and disease. While miRNAs have been demonstrated to play a pivotal role in aspects of cancer biology, these reports have generally focused on the regulation of single genes. Such single-gene approaches have significant limitations, relying on miRNA expr...

journal_title：Breast cancer research and treatment

authors： Pillai MM,Gillen AE,Yamamoto TM,Kline E,Brown J,Flory K,Hesselberth JR,Kabos P

更新日期：2014-07-01 00:00:00

abstract：:EMSY is a putative oncogene amplified in a minority of breast carcinomas, its protein product interacts with and transcriptionally silences BRCA2. We hypothesized that breast tumors from BRCA2 mutation carriers would be less likely than other familial breast cancers to exhibit EMSY amplification. As EMSY is located on...

journal_title：Breast cancer research and treatment

authors： Bane AL,Mulligan AM,Pinnaduwage D,O'Malley FP,Andrulis IL

更新日期：2011-06-01 00:00:00

abstract：PURPOSE:The prognosis of elderly patients with hormone receptor-positive breast cancer is very good, and their survival is unaffected by performing breast-conserving surgery (BCS) without radiotherapy. Therefore, we aimed to verify that BCS without axillary lymph node dissection, sentinel lymph node biopsy, or radiothe...

journal_title：Breast cancer research and treatment

authors： Zhong Y,Xu Y,Zhou Y,Mao F,Lin Y,Guan J,Shen S,Pan B,Wang C,Peng L,Huang X,Li Y,Wang X,Sun Q

更新日期：2020-07-01 00:00:00

abstract：PURPOSE:The malignant upgrade rate of flat epithelial atypia (FEA) diagnosed on core needle biopsy varies between 0 and 30%. Excision versus observation with radiological follow-up for these lesions remains controversial. We hypothesize that the local rate of FEA is low and that close radiological surveillance is a rea...

journal_title：Breast cancer research and treatment

authors： DiPasquale A,Silverman S,Farag E,Peiris L

更新日期：2020-01-01 00:00:00

abstract：:Although breast cancer familial aggregation has been studied in Caucasians, information for African-Americans is scant. We used family cancer history from the Women's Contraceptive and Reproductive Experiences study to assess the aggregation of breast and gynecological cancers in African-American and Caucasian familie...

journal_title：Breast cancer research and treatment

authors： Simon MS,Korczak JF,Yee CL,Daling JR,Malone KE,Bernstein L,Marchbanks PA,Folger SG,McDonald JA,Norman SA,Strom BL,Deapen D,Ursin G,Burkman RT,Press MF,Schwartz AG,Spirtas R

更新日期：2005-02-01 00:00:00

abstract：:Meta-analyses of microarray data indicate that GATA3 is co-expressed with estrogen receptor alpha (ER) in breast cancer cells. While the significance of this remains unclear, it is thought that GATA3 may serve as a prognostic indicator in breast tumors and may play a role in ER signaling. Recently, reciprocal regulati...

journal_title：Breast cancer research and treatment

authors： Licata LA,Hostetter CL,Crismale J,Sheth A,Keen JC

更新日期：2010-07-01 00:00:00

abstract：PURPOSE:TP53 mutation is the most common mutation in breast cancer, and it is considered a target marker of triple-negative breast cancer (TNBC). We investigated whether expression of p53 detected by immunochemical staining predicts the chemotherapy response of TNBC. METHODS:A total of 11,393 TNBC patients who had bet...

journal_title：Breast cancer research and treatment

authors： Bae SY,Nam SJ,Jung Y,Lee SB,Park BW,Lim W,Jung SH,Yang HW,Jung SP

更新日期：2018-11-01 00:00:00

abstract：:Steroid receptor coactivators are important in regulating the function of the receptors in endocrine organ development and in cancers, including breast. Androgen receptor (AR) coactivator ARA70, was first identified as a gene fused to the ret oncogene and later characterized as an AR coactivator. We previously reporte...

journal_title：Breast cancer research and treatment

authors： Wu X,Chen F,Sahin A,Albarracin C,Pei Z,Zou X,Singh B,Xu R,Daniels G,Li Y,Wei J,Blake M,Schneider RJ,Cowin P,Lee P

更新日期：2011-07-01 00:00:00

abstract：:(-)-Epigallocatechin (EGC), one of green tea polyphenols, has been shown to inhibit growth of cancer cells. However its mechanism of action is poorly known. We show here that EGC strongly inhibited the growth of breast cancer cell lines (MCF-7 and MDA-MB-231) but not that of normal breast epithelial cells. The inhibit...

journal_title：Breast cancer research and treatment

authors： Vergote D,Cren-Olivé C,Chopin V,Toillon RA,Rolando C,Hondermarck H,Le Bourhis X

更新日期：2002-12-01 00:00:00

abstract：:The mammalian target of rapamycin complex 1 (mTORC1) is a downstream of the PI3K/Akt pathway which affects cancer development. mTORC1 has many downstream signalling effectors that can enhance different cellular responses. This study aims to investigate the expression of mTORC1 in breast cancer (BC) and correlate it wi...

journal_title：Breast cancer research and treatment

authors： Jerjees DA,Negm OH,Alabdullah ML,Mirza S,Alkaabi M,Hameed MR,Abduljabbar R,Muftah A,Nolan CC,Green AR,Tighe PJ,Band V,Ellis IO,Rakha EA

更新日期：2015-02-01 00:00:00

abstract：:CH50, a recombinant CBD-HepII polypeptide of human fibronectin, was shown to suppress tumor metastasis in murine hepatocarcinoma and melanoma models. However, the effect of CH50 on human cancer cells is still not clear. Here we evaluated the efficiency of CH50 delivered by recombinant adeno-associated virus (rAAV) vec...

journal_title：Breast cancer research and treatment

authors： He ZH,Lei Z,Zhen Y,Gong W,Huang B,Yuan Y,Zhang GM,Wang XJ,Feng ZH

更新日期：2014-01-01 00:00:00

abstract：:Complete remissions in patients with metastatic breast cancer using endocrine therapy or chemotherapy are infrequent. Breast tumors are known to be heterogeneous with respect to estrogen receptor status, and the low complete remission rate may be related to this biochemical heterogeneity. Based on laboratory experimen...

journal_title：Breast cancer research and treatment

authors： Allegra JC,Woodcock TM,Richman SP,Bland KI,Wittliff JL

更新日期：1982-01-01 00:00:00

abstract：:Progesterone, through its nuclear receptors (PR), regulates the development and growth of breast cancers. PR also serve as markers of hormone dependence and prognosis in patients with this disease, and functional PR are required to mediate the antiproliferative effects of progestin therapies. We find that normal and m...

journal_title：Breast cancer research and treatment

authors： Richer JK,Lange CA,Wierman AM,Brooks KM,Tung L,Takimoto GS,Horwitz KB

更新日期：1998-04-01 00:00:00

abstract：:NSABP B-43 is the first prospective, randomized phase III multi-institution clinical trial targeting high-risk, HER2-positive DCIS. It compares whole breast irradiation alone with WBI given concurrently with trastuzumab in women with HER2-positive DCIS treated by lumpectomy. The primary aim is to determine if trastuzu...

journal_title：Breast cancer research and treatment

authors： Siziopikou KP,Anderson SJ,Cobleigh MA,Julian TB,Arthur DW,Zheng P,Mamounas EP,Pajon ER,Behrens RJ,Eakle JF,Leasure NC,Atkins JN,Polikoff JA,Seay TE,McCaskill-Stevens WJ,Rabinovitch R,Costantino JP,Wolmark N

更新日期：2013-11-01 00:00:00

abstract：PURPOSE:Clinical trials demonstrated adjuvant aromatase inhibitor treatment is superior for decreasing breast cancer recurrence risk over adjuvant tamoxifen treatment as early as 2001. Yet clinical use for adjuvant treatment was not recommended by the American Society of Clinical Oncology until 2004. Aromatase inhibito...

journal_title：Breast cancer research and treatment

authors： Aiello EJ,Buist DS,Wagner EH,Tuzzio L,Greene SM,Lamerato LE,Field TS,Herrinton LJ,Haque R,Hart G,Bischoff KJ,Geiger AM

更新日期：2008-02-01 00:00:00

abstract：:Many patients with metastatic breast cancer receive several types of chemotherapy, although it is recognized that there is a declining probability of response. A major problem confronts oncologists in deciding when to recommend to patients that no further chemotherapy should be given. To address this problem we have a...

journal_title：Breast cancer research and treatment

authors： McLachlan SA,Pintilie M,Tannock IF

更新日期：1999-04-01 00:00:00

abstract：:Eribulin mesylate, a novel non-taxane microtubule dynamics inhibitor, is approved for treatment of metastatic breast cancer (MBC) in patients who have previously received at least 2 chemotherapeutic regimens for MBC that should have included an anthracycline and a taxane in the adjuvant or metastatic setting. This pha...

journal_title：Breast cancer research and treatment

authors： McIntyre K,O'Shaughnessy J,Schwartzberg L,Glück S,Berrak E,Song JX,Cox D,Vahdat LT

更新日期：2014-07-01 00:00:00

abstract：:The 2008 Physical Activity (PA) Guidelines recommend engaging in at least 2.5 h (10 MET-hours/week) of moderate intensity PA per week (defined as 4 METs) to reduce risk of morbidity and mortality. This analysis was conducted to investigate whether this recommendation can be extended to breast cancer survivors. Data fr...

journal_title：Breast cancer research and treatment

authors： Beasley JM,Kwan ML,Chen WY,Weltzien EK,Kroenke CH,Lu W,Nechuta SJ,Cadmus-Bertram L,Patterson RE,Sternfeld B,Shu XO,Pierce JP,Caan BJ

更新日期：2012-01-01 00:00:00

abstract：:Oestrogen receptor (ER) negative breast cancers are more likely to achieve a pathological complete response (pCR) to neoadjuvant chemotherapy compared to those with ER positive tumours. ER positive tumours exhibit low proliferation and ER negative cancers high proliferation. The aim of this study was to determine to w...

journal_title：Breast cancer research and treatment

authors： Jones RL,Salter J,A'Hern R,Nerurkar A,Parton M,Reis-Filho JS,Smith IE,Dowsett M

更新日期：2010-01-01 00:00:00

abstract：BACKGROUND:Follow-up after breast cancer treatment is standard due to the risk of development of new primary cancers and recurrent disease. The aim of the present study was to evaluate a standard follow-up program in an oncological department by assessing: (1) Symptoms or signs of new primary cancer or recurrent diseas...

journal_title：Breast cancer research and treatment

authors： Ellegaard MB,Grau C,Zachariae R,Jensen AB

更新日期：2017-08-01 00:00:00

abstract：:Estrogen receptor alpha (ERalpha) is a well-known target for signaling pathways originating from growth factor receptors. Reactive oxygen species (ROS) can induce activation of extracellular response kinase 1/2 (Erk1/2) and protein kinase B (Akt). Both kinases have been implicated in the phosphorylation of serine 118 ...

journal_title：Breast cancer research and treatment

authors： Weitsman GE,Weebadda W,Ung K,Murphy LC

更新日期：2009-11-01 00:00:00

abstract：:Gene fusions have long been considered principally as the oncogenic events of hematologic malignancies, but have recently gained wide attention in solid tumors due to several milestone discoveries and the advancement of deep sequencing technologies. With the progress in deep sequencing studies of breast cancer transcr...

journal_title：Breast cancer research and treatment

authors： Veeraraghavan J,Ma J,Hu Y,Wang XS

更新日期：2016-07-01 00:00:00

abstract：:In view of the essential role of transforming growth factorβ1 (TGFB1) on both inhibiting the development of early benign breast tumors as well as promoting tumor invasion, the association of TGFB1 L10P polymorphism and breast cancer risk has been widely reported, but results of previous studies were somewhat contradic...

journal_title：Breast cancer research and treatment

authors： Ma X,Chen C,Xiong H,Li Y

更新日期：2010-11-01 00:00:00

abstract：:To determine whether atypical antipsychotics, when compared to typical antipsychotics, increase the risk of breast cancer. We conducted a retrospective cohort study using a nested case-control analysis within the United Kingdom General Practice Research Database population. We identified all female patients prescribed...

journal_title：Breast cancer research and treatment

authors： Azoulay L,Yin H,Renoux C,Suissa S

更新日期：2011-09-01 00:00:00